MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Intra-abdominal Infection
Conditions
Intra-abdominal Infection, Complicated Intra-abdominal Infection
Trial Timeline
Apr 8, 2016 → Jul 28, 2017
NCT ID
NCT02739997About MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg is a phase 3 stage product being developed by Merck for Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02739997. Target conditions include Intra-abdominal Infection, Complicated Intra-abdominal Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02739997 | Phase 3 | Completed |
Competing Products
20 competing products in Intra-abdominal Infection